{
  "trial_id": "NCT02811120",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "willing and able to give written informed consent",
      "label": "met",
      "evidence": "patient text"
    },
    {
      "criterion": "originally enrolled in the randomised parallel group study of quadrivalent meningococcal vaccination",
      "label": "met",
      "evidence": "patient text"
    }
  ],
  "exclusion": [
    {
      "criterion": "known bleeding diathesis (or any condition that may be associated with a prolonged bleeding time)",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "any other significant condition or circumstance which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "The patient has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%. He was treated with plasma exchange and corticosteroids for atypical hemolytic uremic syndrome.",
  "_meta": {
    "topic_id": "68",
    "trial_id": "NCT02811120",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}